This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast To 2022





NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01158446/EpiCast-Report-Dry-Eye-Syndrome---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022

Summary

Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. It results in symptoms of discomfort such as visual disturbance and tear film instability (DEWS, 2007). Middle-aged and older adults are the most commonly affected group because of the high prevalence of contact lens usage, systemic drug effects, autoimmune diseases, and refractive surgeries in these group (Davis, 2003; Glasson et al., 2003; Schaumberg et al., 2002; Schaumberg et al., 2003; Toda et al., 2001).

Globally, dry eye has a prevalence of up to 33% (Clegg et al., 2006; Lemp et al., 2008; Schaumberg et al., 2002; Shimmura et al., 1999). The prevalence of dry eye is estimated to range from <0.1% to 33% across different countries and varies between 5% to >30% in various ages groups worldwide (Clegg et al., 2006; Lemp et al., 2008; Shimmura et al., 1999). Research also shows that dry eye syndrome is more prevalent in women than in men (Schaumberg et al., 2002).

Scope

- The Dry Eye Syndrome, EpiCast Report provides an overview of the risk factors and global trends of dry eye syndrome in the nine major markets (US, France, Germany, Italy, Spain, UK, Japan, China, and India). - It also includes a 10-year epidemiology forecast of the prevalent cases of dry eye syndrome, segmented by age (given in five-year increments beginning at age 45 years and ending at ages 85 years and older), sex, and severity in these markets.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global dry eye syndrome market.- Quantify patient populations in the global dry eye syndrome market to improve product design, pricing, and launch plans.- Organize sales and marketing efforts by identifying the age groups, sex, and severity levels that present the best opportunities for dry eye syndrome therapeutics in each of the markets covered.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,150.37 +70.23 0.39%
S&P 500 2,124.88 +7.19 0.34%
NASDAQ 5,115.39 +23.3050 0.46%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs